| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 01:30 | Cloud infrastructure company Ionic Digital announces Nasdaq direct listing set for July 28, potentially valuing it at $2 billion | ||
| 00:30 | Latin American ticket marketplace Ticketplus lowers deal size by 33% ahead of $17 million US IPO | ||
| Di | SPAC ARC Group Securities Acquisition II lowers units offered by 33%, replaces management and sponsor ahead of $100 million IPO | ||
| Di | SPAC Southern Cross Acquisition I prices $100 million IPO, targeting businesses with revenue visibility | ||
| Di | SPAC B&R Technology Merger prices $325 million IPO, targeting tech with AI tailwinds | ||
| Di | Orbital systems developer Gravitics Holdings files for a $125 million Nasdaq listing | ||
| Mo | SPAC TCGX Acquisition files for a $75 million IPO, targeting healthcare in Asia | ||
| Mo | Womenswear brand Reformation sets terms for $225 million IPO | ||
| Mo | Cardiovascular disease biotech Scribe Therapeutics sets terms for $100 million IPO | ||
| Mo | Blackstone-backed sandwich chain Jersey Mike's Subs sets terms for $1.0 billion IPO | ||
| Sa | US IPO Weekly Recap: Csquare and Standard Nuclear both underwhelm amid cautious market | ||
| Fr | US IPO Week Ahead: Quiet IPO calendar primed for potential launches | ||
| Fr | Hypoxia-focused biotech NuvOx Therapeutics files for a $20 million IPO | ||
| Fr | Acute and chronic pain relief biotech Latigo Biotherapeutics files for a $100 million IPO | ||
| Fr | The 2Q26 IPO Market's Law Firm Leaderboard | ||
| Fr | Cancer therapies biotech BlossomHill Therapeutics files for a $100 million IPO | ||
| Fr | SPAC AMR Resources Acquisition prices $250 million IPO, targeting critical minerals | ||
| Do | SPAC Phalanx Acquisition I files for a $175 million US IPO, targeting financial services | ||
| Do | Cloud computing service provider QumulusAI completes its Nasdaq direct listing | ||
| Do | Small modular reactor fuel developer Standard Nuclear prices previously downsized IPO at $15 | ||
| Do | Data center operator Csquare prices IPO at $21, below the range | ||
| Do | Metabolic disorders biotech Vogenx files for a US IPO | ||
| 15.07. | Michael Klein's SPAC Churchill Capital XIII files for a $300 million IPO | ||
| 15.07. | Israel-based ocular disease biotech Tarsier Pharma ups shares offered by 11% ahead of $50 million US IPO | ||
| 15.07. | Cardiovascular diseases biotech Braveheart Bio files for a $100 million IPO |